Biotech Values

[mcbio]

DVAX-GSK deal on TLR8s

[It's about time they focused on TLR8s. LOL]

http://www.bizjournals.com/sanfrancisco/news/2011/10/21/dynavax-to-get-3-million-glaxosmithkline.html?ana=yfcpc

Dynavax to get $3 million in expanded GlaxoSmithKline deal

San Francisco Business Times by Steven E.F. Brown, Web Editor
Date: Friday, October 21, 2011, 9:45am PDT - Last Modified: Friday, October 21, 2011, 9:47am PDT..

Dynavax Technologies Corp. .. added a new target to a research deal with giant GlaxoSmithKline PLC, and will get a $3 million milestone payment as a result.

Berkeley-based Dynavax (NASDAQ: DVAX) and GlaxoSmithKline (NYSE: GSK) added a new “toll-like receptor,” TLR8, to their agreement. They plan to study TLR8 and seek an inhibitor of it to treat autoimmune and inflammatory diseases.

Autoimmune diseases, like rheumatoid arthritis, are when the body’s defenses attack its own tissues.

Dino Dina, M.D., is CEO of Dynavax. The company’s main push these days is on Heplisav, a vaccine for hepatitis B now in Phase III testing.

Andrew Witty is CEO of GlaxoSmithKline, which is based in the United Kingdom.